Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

Romidepsin (12mg/ m\^2) will be administered on days 1 and 10 of each cycle through a peripheral or central intravenous catheter for 6 cycles.

Lenalidomide will be administered by oral intake in a dose-escalation with a starting dose of 5mg daily, a second dose level of 10mg daily, a third dose level at 15mg daily, and a fourth dose level at 20mg daily on days -7 to day 10 of first cycle. After the second cycle, lenalidomide will be given from day 1 to day 10 in each cycle for up to 6 cycles.

CC-486 (5-azacitidine) with a dose of 300mg oral intake daily will be given on day 1 to day 10 for 6 cycles.

Dexamethasone, 40mg, by mouth (PO), will be given on days 1 and 10 of each cycle.

Screening

Baseline, end of treatment and disease progression, and Day 30 (+7).

Baseline, every 2 cycles, end of treatment and disease progression, and follow-up.

Baseline, every 2 cycles, end of treatment and disease progression, and follow-up.

Screening